Core Insights - Callan JMB Inc. is participating in the DealFlow Discovery Conference on January 28-29, 2026, highlighting its role in the healthcare logistics sector [1][2]. Company Overview - Callan JMB Inc. is a vertically integrated logistics company focused on empowering the healthcare industry and emergency management agencies through services such as fulfillment, storage, monitoring, and cold chain logistics [3]. - The company aims to secure medical materials and protect patients and communities by providing compliant, safe, and effective medicines [3]. - Callan JMB boasts expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance, and emergency preparedness, positioning itself as a leader in the industry [3]. - The company emphasizes a gold standard in client experience, offering customizable interfaces, reliable shipping, and environmentally sustainable specialty packaging [3].

Core Insights - PainReform Ltd. announced a name change and is expanding into diversified healthcare and AI-driven energy platforms, resulting in a 27.4% increase in share price to $1.02 in pre-market trading [1] Gainers - Acco Group Holdings Limited saw a significant gain of 219.4%, reaching $9.40 in pre-market trading [4] - Venus Concept Inc. increased by 72.2% to $2.48 [4] - Jaguar Health, Inc. rose 41.3% to $1.08 following a licensing agreement with Woodward Specialty [4] - ImmunityBio, Inc. gained 22.8% to $4.85, with preliminary net product revenue for Anktiva projected at approximately $113 million for fiscal 2025, marking a 700% year-over-year increase [4] - OneMedNet Corporation rose 14.2% to $0.9711 after a previous decline [4] - Brand Engagement Network, Inc. increased by 13.8% to $6.50 [4] - Springview Holdings Ltd rose 13.4% to $19.75 after a substantial 657% increase on Thursday [4] - Creative Global Technology Holdings Limited gained 10.7% to $4.22 after a 52% jump on Thursday [4] - Kopin Corporation increased by 8.1% to $3.20 [4] Losers - Callan JMB Inc. fell 20.7% to $3.33 after a 275% increase on Thursday due to a strategic agreement with Biostax Corp [4] - Erayak Power Solution Group Inc. decreased by 18.3% to $3.21 after an 18% rise on Thursday [4] - TryHard Holdings Limited dropped 16.4% to $6.35 following a 76% decline on Thursday due to a joint venture announcement [4] - iOThree Limited shares dipped 15% to $2.56 [4] - NOVONIX Limited fell 14% to $1.17 [4] - Moolec Science SA tumbled 13.1% to $6.69 after an 118% increase on Thursday [4] - High Roller Technologies, Inc. declined 12.9% to $20.64 after a 25% rise on Thursday [4] - Bonk, Inc. fell 10.4% to $3.55 after a 42% increase on Thursday due to acquisition news [4] - J B Hunt Transport Services Inc fell 4.2% to $197.86, reporting mixed financial results for the fourth quarter [4] - QXO Inc dipped 3.5% to $24.14 after announcing a $750 million stock offering and preliminary fourth-quarter net sales of $2.19 billion [4]

分组1 - Callan JMB Inc. (NASDAQ:CJMB) is currently trading at $4.03 with a target price of $2.04, indicating a potential downside of approximately -49.35% [1][5] - PS International Group Ltd. (PSIG) is trading at $4.28, with a discounted cash flow (DCF) valuation of $4.57, resulting in a positive price percentage difference of 6.68% [2][5] - The contrasting market outlook for CJMB and PSIG highlights the challenges faced by CJMB, as its target price is significantly lower than its current market price, while PSIG's DCF valuation exceeds its trading price [3][5] 分组2 - The negative sentiment surrounding CJMB, along with its exclusion from analyst coverage, emphasizes a lack of confidence in the stock's future performance [4] - In contrast, PSIG's positive outlook and potential upside make it a more attractive option for investors seeking growth opportunities in the same industry [4]

Company Highlights - Ambitions Enterprise Management Co. L.L.C (NASDAQ:AHMA) saw its stock price rise to $28.03, marking an 80.88% increase, driven by strong performance in the MICE and tourism sectors [1][7] - authID Inc. (NASDAQ:AUID) experienced a stock price increase to $1.77, a 78.34% rise, reflecting the growing demand for secure, biometric identity verification solutions [2][7] - CALLAN JMB INC. (NASDAQ:CJMB) saw its stock price surge to $3.91, a 249.12% increase, as it shifts towards cold-chain infrastructure to support the $100 billion GLP-1 pharmaceutical market [3][7] - Moolec Science S.A. (NASDAQ:MLEC) experienced a 101.42% increase in its stock price to $7.11, indicating market interest in alternative protein sources and sustainable food technologies [4] - Springview Holdings Ltd (NASDAQ:SPHL) saw its stock price jump to $15.9, a staggering 606.67% increase, highlighting robust demand in the construction sector [5] Industry Trends - The movements in stock prices reflect diverse sectors experiencing growth, including technology, biotechnology, logistics, and construction, indicating broader economic trends and investor interests [6] - Strategic initiatives and partnerships by these companies demonstrate a proactive approach to capitalizing on market opportunities and addressing industry demands [6]

Market Performance - U.S. stocks showed positive movement, with the Nasdaq Composite increasing by approximately 1% on Thursday. The Dow rose by 0.80% to 49,543.16, while the S&P 500 gained 0.74% to 6,977.92 [1] - Information technology shares experienced a gain of 1.5%, while health care stocks saw a decline of 1.5% on the same day [1] Job Market - Initial jobless claims in the U.S. decreased by 9,000 to 198,000 for the week ending January 10, which was better than market expectations of 215,000 [2][10] Commodity Prices - Oil prices fell by 4.7% to $59.08, while gold decreased by 0.4% to $4,618.80. Silver and copper also saw declines of 1.1% to $90.405 and 1.5% to $5.9660, respectively [5] European Market Overview - European shares displayed mixed results, with the eurozone's STOXX 600 rising by 0.39%, while Spain's IBEX 35 Index fell by 0.21%. London's FTSE 100 gained 0.56%, Germany's DAX rose slightly by 0.01%, and France's CAC 40 slipped by 0.23% [6] Asian Market Overview - Asian markets closed lower, with Japan's Nikkei down by 0.42%, Hong Kong's Hang Seng Index declining by 0.28%, and China's Shanghai Composite falling by 0.33% [7] Company News - Callan JMB Inc. shares surged by 208% to $3.45 following a strategic teaming agreement with Biostax Corp [9] - Springview Holdings Ltd saw a significant increase of 290% to $8.96 after announcing a partnership with Jiangsu GSO New Energy Technology Co. for solar solutions in Singapore [9] - authID Inc. shares rose by 99% to $1.98 due to an integration announcement with ServiceNow [9] - MetaVia Inc. shares dropped by 40% to $3.26 after pricing an $8.1 million public offering [9] - Caledonia Mining Corporation PLC shares fell by 19% to $26.39 after announcing a $125 million offering of convertible senior notes [9] - TryHard Holdings Limited shares decreased by 41% to $19.00 following a memorandum of cooperation with STAR PARTY HK LIMITED for a potential joint venture in Japan [9]

Core Insights - Callan JMB Inc. has entered a strategic teaming agreement with Attune Biotech to enhance federal contract capabilities and expedite the deployment of Attune's therapeutic pipeline [1][2][6] Group 1: Agreement Details - Callan JMB will provide federal oversight services, including quality assurance, compliance with BARDA contracts, FDA audit readiness, and supply chain governance [2][5] - The partnership aims to generate approximately $50 to $75 million in combined revenue over the next five years, with Callan JMB's share estimated at $25 million to $45 million [5] Group 2: Operational Capabilities - Callan JMB has experience managing national stockpile assets for various federal agencies, allowing for immediate deployment capabilities that typically take years to establish [3][6] - A surge-readiness simulation was successfully completed, validating the platform for 24-hour emergency deployment and regional distribution within 48 hours [4] Group 3: Attune's Therapeutic Pipeline - Attune's pipeline includes Lodonal, a TLR4 antagonist for immune restoration, MENK-201, a peptide therapeutic for HIV and pancreatic cancer, and Cytocide-100, an antimicrobial platform [7][8][9] - Lodonal is currently in development across five clinical programs and has transitioned to fully U.S.-based cGMP production with a validated surge capacity of over 500,000 units [7]

Revenue Performance - Revenue for the three months ended September 30, 2025, was $1,446,917, a 1% increase from $1,435,376 in the same period of 2024[131] - Revenue for the nine months ended September 30, 2025, was $4,562,604, a 12% decrease from $5,211,665 in the same period of 2024[132] Profit and Loss - Gross profit for the three months ended September 30, 2025, was $493,307, a 6% increase from $464,445 in the same period of 2024[131] - Net loss for the three months ended September 30, 2025, was $(2,731,341), a 239% increase from $(804,987) in the same period of 2024[131] Expenses - Selling, general and administrative expenses for the three months ended September 30, 2025, were $2,372,465, a 90% increase from $1,245,428 in the same period of 2024[134] - The Company reported a significant increase in consulting and professional fees, rising by $304,136 for the three months ended September 30, 2025, due to preparations for its initial public offering[134] Cash Flow - Cash used in operating activities for the nine months ended September 30, 2025, was $(3,887,737), a decrease of $(5,151,263) compared to cash provided by operating activities of $1,263,526 in the same period of 2024[140] - Cash provided by financing activities for the nine months ended September 30, 2025, was $5,196,432, an increase of $8,760,108 compared to $(3,563,676) in the same period of 2024[142] Financing Activities - The Company entered into an ELOC Facility allowing the sale of up to $25 million of common stock, with 123,208 shares issued for net proceeds of approximately $497,750 as of September 30, 2025[136][138] Seasonal Trends - The Company expects seasonal revenue fluctuations, typically highest in the third and fourth quarters and lowest in the first and second quarters[130]

Financial Performance - Revenues for Q3 2025 were $1.4 million, a slight increase from $1.4 million in Q3 2024, while revenues for the nine months ended September 30, 2025, were $4.6 million, down from $5.2 million in the same period last year [12]. - Gross profit for Q3 2025 was $0.5 million, compared to $0.5 million in Q3 2024, and for the nine months ended September 30, 2025, gross profit was $1.8 million, down from $2.1 million in the prior year [12]. - Loss from operations for Q3 2025 was ($1.9) million, compared to a loss of ($0.8) million in Q3 2024, and for the nine months ended September 30, 2025, the loss was ($4.5) million, up from ($1.0) million in the prior year [12]. - Net income for the nine months ended September 30, 2025, was a loss of $5,373,327, compared to a loss of $998,596 for the same period in 2024 [14]. - Net cash provided by (used in) operating activities was $(3,887,737) for the nine months ended September 30, 2025, compared to $1,263,526 in 2024 [14]. - Cash flows used in investing activities totaled $(616,896) for the nine months ended September 30, 2025, compared to $(46,167) in 2024 [14]. - Net cash provided by financing activities was $5,196,432 for the nine months ended September 30, 2025, compared to $(3,563,676) in 2024 [14]. - The company reported stock-based compensation of $1,154,842 for the nine months ended September 30, 2025 [14]. - The company experienced a decrease in accounts receivable of $(395,995) compared to an increase of $1,803,724 in 2024 [14]. - The company reported a decrease in inventory of $(64,883) for the nine months ended September 30, 2025, compared to an increase of $7,086 in 2024 [14]. - Proceeds from IPO and overallotment, net, amounted to $4,543,988 for the nine months ended September 30, 2025 [14]. - The company had a cash flow increase of $691,799 in cash and cash equivalents for the nine months ended September 30, 2025, compared to a decrease of $(2,346,317) in 2024 [14]. Operational Developments - The Company extended its emergency preparedness contract with the City of Chicago through June 2026, increasing total contract value to $9.1 million with an additional $1.5 million in funding [6]. - The Company established a subsidiary in India, Callan JMB Services (India) Private Limited, with plans for a temperature-controlled warehouse for pharmaceutical storage and distribution [6]. - The Company upgraded its Sentry Monitoring System to version 4.0, enhancing temperature monitoring capabilities for healthcare facilities and emergency management agencies [6]. - The Company entered a preliminary agreement to install oral drug delivery equipment at its cGMP facility in Texas, supporting future logistics operations for international pharmaceutical companies [6]. Cash and Assets - Cash and cash equivalents as of September 30, 2025, were $2.8 million, an increase from $2.1 million at the end of 2024 [10]. - Total assets as of September 30, 2025, were $7.7 million, compared to $5.1 million at the end of 2024 [10]. - Cash and cash equivalents at the end of the period were $2,789,744, a decrease from $2,809,303 at the end of the same period in 2024 [14].

Core Insights - Callan JMB Inc. is expanding its logistics platform into the food sampling industry and has entered agreements to enhance its pharmaceutical logistics capabilities [1][2][3] - The company has established a subsidiary in India to support temperature-controlled pharmaceutical storage and distribution [2][3] - A long-term contract with the City of Chicago has been extended through June 2026, with an increase in funding [2][3] Business Developments - The company has launched operations in the food sampling sector as part of its strategic growth initiatives [2][3] - A preliminary agreement has been made to install oral drug delivery system manufacturing equipment in Texas [2][3] - Callan JMB Services (India) Private Limited has been formed, with plans for a temperature-controlled warehouse in Pune, Maharashtra [2][3] Financial Performance - Revenues for Q3 2025 were $1.4 million, a slight increase from $1.4 million in Q3 2024, while revenues for the nine months ended September 30, 2025, were $4.6 million, down from $5.2 million in the same period last year [8][10] - Gross profit for Q3 2025 was $0.5 million, compared to $0.46 million in Q3 2024, and for the nine months ended September 30, 2025, it was $1.8 million, down from $2.1 million [8][11] - The company reported a net loss of $2.7 million for Q3 2025, compared to a loss of $0.8 million in Q3 2024, and a net loss of $5.4 million for the nine months ended September 30, 2025, compared to a loss of $1.0 million in the same period last year [10][11] Technology Enhancements - The Sentry Monitoring System has been upgraded to version 4.0, allowing for improved temperature monitoring capabilities across devices [2][3]

Core Insights - Callan JMB has entered a preliminary agreement to install innovative manufacturing equipment for oral drug delivery in its cGMP facility in Texas, aligning with its strategy to support onshoring of logistical and operational activities for international companies [1][2][3] Group 1: Company Developments - The collaboration will combine Callan JMB's capabilities in cGMP warehousing, licensing, certification, and drug distribution with the new client's manufacturing technology for oral fast-dissolving strips, providing alternatives to intravenous injections for over-the-counter medicines [2][3] - The CEO of Callan JMB expressed excitement about the partnership, highlighting the potential for safe and effective oral drug delivery and the alignment with the company's goals for expansion into innovative healthcare technologies [3] - This agreement represents a progression from Callan JMB's existing storage and distribution capabilities into sourcing and utilizing Active Pharmaceutical Ingredients (APIs) in new manufacturing processes, with plans for further initiatives with global healthcare manufacturing leaders [3] Group 2: Company Overview - Callan JMB is an integrative logistics company focused on empowering the healthcare industry and emergency management agencies through services such as fulfillment, storage, monitoring, and cold chain logistics to ensure the safety and compliance of medical materials [4] - The company boasts expertise in supply chain logistics, thermodynamics, biologics, inventory management, regulatory compliance, and emergency preparedness, aiming to provide a high standard of client experience with customizable interfaces and reliable shipping [4]